<DOC>
	<DOCNO>NCT00014586</DOCNO>
	<brief_summary>RATIONALE : Testosterone stimulate growth cancer cell . Bicalutamide goserelin may fight prostate cancer reduce production testosterone . It yet know hormone therapy regimen effective prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness bicalutamide observation follow bicalutamide plus either goserelin orchiectomy patient prostate cancer .</brief_summary>
	<brief_title>Bicalutamide Compared With Observation Followed Bicalutamide Plus Either Goserelin Orchiectomy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall cancer-specific survival patient prostate cancer treat bicalutamide alone follow bicalutamide either goserelin bilateral orchiectomy v observation follow bicalutamide either goserelin bilateral orchiectomy . - Compare time first second clinical progression patient treat regimen . - Compare quality life , include potency , patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , tumor differentiation grade ( G3 Gleason 6 v value ) , T category , comorbidity ( i.e. , chronic disease ) ( yes v ) , potency ( yes v ) , type choose hormonal ablation ( goserelin v orchiectomy ) , PSA level ( le 10 ng/mL vs 10-20 ng/mL v 20-100 ng/mL ) , N status ( N0 v NX ) . Patients randomize one two treatment arm . - Arm I : Patients receive oral bicalutamide daily . At first symptomatic disease progression , patient also receive goserelin subcutaneously every 28 84 day undergo bilateral orchiectomy . At second disease progression , patient discontinue bicalutamide . - Arm II : Patients observe first symptomatic disease progression . At first disease progression , patient receive bicalutamide either goserelin bilateral orchiectomy arm I . Patients discontinue bicalutamide arm I . Quality life assess baseline , every 6 month 6 year , disease progression , annually thereafter . Patients follow annually . PROJECTED ACCRUAL : Approximately 1266 patient ( 633 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer T13 , G ( Gleason ) , N0 NX High risk define G3 Gleason 6 PSA 20 ng/mL unfit unwilling undergo local curative therapy OR Low risk define G12 Gleason le 7 PSA 20 ng/mL prior local curative therapy Asymptomatic ( pain score 0 ) PSA 100 ng/mL ( 25 time normal ) No metastatic disease chest xray , bone scan ( PSA 10 ng/mL 2.5 time normal ) , pelvic CT ( chance lymph node metastasis least 5 % Partin table ) No bone disease would interfere diagnosis metastatic disease PATIENT CHARACTERISTICS : Age : 80 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy within past 5 year except adequately treat basal cell skin cancer No psychological , personal , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>